You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠集團(000513.SZ)獲授予TY2136b項目在中國地區的獨家開發及商業化權利
格隆匯 08-31 16:59

格隆匯 8 月 31日丨麗珠集團(000513.SZ)公佈,公司2020831日與浙江同源康醫藥股份有限公司(“同源康醫藥”)簽署了《專利轉讓及技術獨佔許可協議》,根據協議,同源康醫藥同意授予公司就TY2136b項目(一種ROS1/NTRK/ALK多激酶小分子抑制劑)及其相關專利在中國地區(包括香港特別行政區、澳門特別行政區和台灣地區)的獨家開發及商業化權利。

次合作進一步拓展了公司在抗腫瘤領域產品的研發管線佈局,符合公司中長期創新藥發展的戰略目標。通過合作,有利於共同發揮雙方的研發優勢及公司在許可區域內成熟的商業化運營優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account